Search

Your search keyword '"Szarek, M."' showing total 276 results

Search Constraints

Start Over You searched for: Author "Szarek, M." Remove constraint Author: "Szarek, M." Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
276 results on '"Szarek, M."'

Search Results

1. Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES

2. Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT

4. Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES

5. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes

6. Evaluation of the benefit of rivaroxaban on VOYAGER PAD primary composite of limb, heart and brain outcomes using the global rank and win ratio methods

7. Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome

9. Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: further insights from the ODYSSEY OUTCOMES trial

10. 575P Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results

11. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab

12. P-125 Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)

13. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

14. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

15. Alirocumab after acute coronary syndrome in patients with a history of heart failure

16. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

17. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

18. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

19. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

21. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial

22. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome

23. Low-density lipoprotein cholesterol <50 mg/dL is an appropriate target after acute coronary syndrome: propensity score-matched analysis of the ODYSSEY OUTCOMES trial

24. Effect of alirocumab on incidence of atrial fibrillation after acute coronary syndromes: insights from ODYSSEY OUTCOMES

26. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

27. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

28. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

29. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

31. Effects of alirocumab on types of myocardial infarction: Insights from the ODYSSEY OUTCOMES trial

32. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

33. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

34. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

35. 4115Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment

36. P1226Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES

37. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

39. Cardiovascular Outcomes With Alirocumab After Acute Coronary Syndrome: Results of the Odyssey Outcomes Trial

42. Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, A Proprotein Convertase Subtilisin/Kexin type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data

44. Activin A target genes are differentially expressed between normal and neoplastic adult human testes: clues to gonocyte fate choice.

48. Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged less than65 Versus =65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)

49. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study

50. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study

Catalog

Books, media, physical & digital resources